{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:22:47Z","timestamp":1787678567902,"version":"build-2784847793"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110212","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:59:58Z","timestamp":1783627198000},"page":"110212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects"],"prefix":"10.1016","volume":"180","author":[{"given":"Kequan","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruicong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2026.110212_bb0005","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.pain.2010.09.030","article-title":"Central sensitization: implications for the diagnosis and treatment of pain","volume":"152","author":"Woolf","year":"2011","journal-title":"Pain"},{"issue":"10180","key":"10.1016\/j.bioorg.2026.110212_bb0010","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(19)30430-1","article-title":"Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia","volume":"393","author":"Colvin","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110212_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114147","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective","volume":"180","author":"Bindu","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110212_bb0020","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/acs.jmedchem.1c00028","article-title":"Novel approaches, drug candidates, and targets in pain drug discovery","volume":"64","author":"Obeng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110212_bb0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2013.01.068","article-title":"Sigma 1 receptor: a new therapeutic target for pain","volume":"716","author":"Zamanillo","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110212_bb0030","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.tips.2019.07.006","article-title":"The molecular function of \u03c3 receptors: past, present, and future","volume":"40","author":"Schmidt","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2026.110212_bb0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1089\/ars.2014.5993","article-title":"The sigma1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control","volume":"22","author":"Rodriguez-Munoz","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bioorg.2026.110212_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-319-50174-1_9","article-title":"Sigma-1 receptor antagonists: a new class of Neuromodulatory analgesics","volume":"964","author":"Sanchez-Fernandez","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bioorg.2026.110212_bb0045","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1111\/bph.14794","article-title":"Sigma-1 receptor modulates neuroinflammation associated with mechanical hypersensitivity and opioid tolerance in a mouse model of osteoarthritis pain","volume":"176","author":"Carcole","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110212_bb0050","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.phrs.2018.02.008","article-title":"Targeting immune-driven opioid analgesia by sigma-1 receptors: opening the door to novel perspectives for the analgesic use of sigma-1 antagonists","volume":"131","author":"Tejada","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110212_bb0055","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1007\/s00213-014-3524-3","article-title":"Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors","volume":"231","author":"Tejada","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bioorg.2026.110212_bb0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2005.01.036","article-title":"Formalin-induced pain is reduced in \u03c31 receptor knockout mice","volume":"511","author":"Cend\u00e1n","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110212_bb0065","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jpain.2012.08.006","article-title":"Role of Sigma-1 receptors in paclitaxel-induced neuropathic pain in mice","volume":"13","author":"Nieto","year":"2012","journal-title":"J. Pain"},{"key":"10.1016\/j.bioorg.2026.110212_bb0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10753-013-9736-6","article-title":"Effects of a selective sigma 1 antagonist compound on inflammatory pain","volume":"37","author":"Parenti","year":"2014","journal-title":"Inflammation"},{"key":"10.1016\/j.bioorg.2026.110212_bb0075","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1007\/s00213-014-3524-3","article-title":"Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors","volume":"231","author":"Tejada","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bioorg.2026.110212_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4155\/ppa-2020-0007","article-title":"Sigma-1 receptor antagonists: promising players in fighting neuropathic pain","volume":"9","author":"Linciano","year":"2020","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.bioorg.2026.110212_bb0085","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1111\/j.1476-5381.2012.01942.x","article-title":"Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization","volume":"166","author":"Romero","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110212_bb0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10753-013-9736-6","article-title":"Effects of a selective sigma 1 antagonist compound on inflammatory pain","volume":"37","author":"Parenti","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.bioorg.2026.110212_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/ejp.4755","article-title":"E-52862\u2014a selective sigma-1 receptor antagonist, in peripheral neuropathic pain: two randomized, double-blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy","volume":"29","author":"G\u00e1lvez","year":"2025","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.bioorg.2026.110212_bb0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2967\/jnumed.113.120261","article-title":"Evaluation of \u03c3-1 receptor radioligand <sup>18<\/sup>F-FTC-146 in rats and squirrel monkeys using PET","volume":"55","author":"James","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110212_bb0105","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1021\/jm00034a020","article-title":"Structural features important for sigma 1 receptor binding","volume":"37","author":"Glennon","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110212_bb0110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nature17391","article-title":"Crystal structure of the human sigma1 receptor","volume":"532","author":"Schmidt","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110212_bb0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110212_bb0120","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1021\/acs.jmedchem.0c02044","article-title":"Structure-enabled discovery of novel macrocyclic inhibitors targeting Glutaminase 1 allosteric binding site","volume":"64","author":"Xu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110212_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140125","article-title":"Discovery of novel thiophene [2,3-D] pyrimidine\u2013thiazole derivative as promising MNK inhibitor to treat breast cancer","volume":"1321","author":"Zhu","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110212_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114860","article-title":"Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors","volume":"245","author":"Zhou","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110212_bb0135","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/jm00038a002","article-title":"Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new .sigma. receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells","volume":"37","author":"John","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110212_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313121","article-title":"Overcoming challenges in small-molecule drug bioavailability: a review of key factors and approaches","volume":"25","author":"Wu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110212_bb0145","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1021\/acs.jmedchem.3c01093","article-title":"Discovery of novel Aminobutanoic acid-based ASCT2 inhibitors for the treatment of non-small-cell lung Cancer","volume":"67","author":"Qin","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110212_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114846","article-title":"The SAR and action mechanisms of autophagy inhibitors that eliminate drug resistance","volume":"244","author":"Ye","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110212_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-026-01426-2","article-title":"Safety considerations for cereblon-recruiting targeted protein degraders","author":"Garside","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110212_bb0160","doi-asserted-by":"crossref","first-page":"17319","DOI":"10.1021\/acs.jmedchem.4c01223","article-title":"Discovery of novel PROTAC SIRT6 degraders with potent efficacy against hepatocellular carcinoma","volume":"67","author":"Huang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110212_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113091","article-title":"Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion","volume":"211","author":"Qiu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110212_bb0170","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/17460441.2024.2306845","article-title":"Molecular glue degraders: exciting opportunities for novel drug discovery","volume":"19","author":"Lemaitre","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110212_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104599","article-title":"Next-generation drug conjugates for breast cancer: clinical prospects and mechanism-based strategies to overcome resistance","volume":"31","author":"Zhao","year":"2026","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2026.110212_bb0180","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:46:17Z","timestamp":1787676377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S0045206826007480"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110212","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110212"}}